Abstract: A pharmaceutical composition comprising a nucleic acid molecule encoding a variable domain deleted E2 polypeptide of HCV (e.g., E2Delta123). The composition is suitable for use, for use, or when used, in the treatment or prevention of HCV infection. The nucleic acid molecule may be DNA or RNA or a modified or synthetic form, or contained within a plasmid, a viral or non-viral vector for vaccination, a polynucleotide expression cassette, or a cell for vector propagation. Methods of administration as prime and boost vaccinations are also provided.

Abstract: The invention provides a modified zeolite, a method of preparing the modified zeolite and a method of one cycle alkylating benzene in presence of one of an unmodified and modified zeolite catalyst. The modified zeolite catalyst includes zeolite with ratio of silica to alumina ranging between 5% to 95% of silica and 95% to 5% alumina, kaolinite and a binder, wherein the zeolite is modified with one or more metal oxides of Lanthanide-series of the Periodic Table. The method of alkylating benzene is one cycle process in presence of a catalyst that includes charging benzene and ethylene gas feedstock to an alkylation zone. Heated benzene and the ethylene gas feedstock are contacted in a fixed bed reactor in the alkylation zone. The catalyst for alkylating benzene is added in a catalyst zone of the fixed bed reactor.

Abstract: Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.

Abstract: Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.

Abstract: The present invention provides antibodies, for use in the treatment, suppression prevention of Filovirus disease, particularly Ebola virus disease. Also provided immunogens for use in eliciting such antibodies.

Abstract: A method of localizing portable apparatus (200) obtains: a stored experience data set comprising a set of connected nodes; captured location representation data provided by at least one sensor associated with the portable apparatus, and a current pose estimate of the portable apparatus within the environment. The pose estimate is used to select a candidate set of the nodes that contain a potential match for the captured location representation data. The pose estimate is used to obtain a set of paths from path memory data, each said path comprising a set of said nodes previously traversed in the environment under similar environmental/visual conditions. The set of paths is used to refine the candidate set. The captured location representation data and the refined candidate set of nodes is compared in order to identify a current pose of the portable apparatus within the environment.

Abstract: A method of localizing portable apparatus (100) in an environment, the method comprising obtaining captured image data representing an image captured by an imaging device (106) associated with the portable apparatus, and obtaining mesh data representing a 3-dimensional textured mesh of at least part of the environment. The mesh data is processed to generate a plurality of synthetic images, each synthetic image being associated with a pose within the environment and being a simulation of an image that would be captured by the imaging device from that associated pose. The plurality of synthetic images is analyzed to find a said synthetic image similar to the captured image data, and an indication is provided of a pose of the portable apparatus within the environment based on the associated pose of the similar synthetic image.

Abstract: A method of localising portable apparatus (100) in an environment, the method comprising obtaining captured image data representing an image captured by an imaging device (106) associated with the portable apparatus, and obtaining mesh data representing a 3-dimensional textured mesh of at least part of the environment. The mesh data is processed to generate a plurality of synthetic images, each synthetic image being associated with a pose within the environment and being a simulation of an image that would be captured by the imaging device from that associated pose. The plurality of synthetic images is analysed to find a said synthetic image similar to the captured image data, and an indication is provided of a pose of the portable apparatus within the environment based on the associated pose of the similar synthetic image.

Abstract: Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.

Abstract: Method and apparatus for localizing transportable apparatus (100) within an environment (120) includes obtaining (202) point cloud data (114) representing a 3D point cloud with appearance information of at least part of the environment. The method further obtains (204) first frame data (110) representing an image produced by a sensor (102) onboard transportable apparatus at a first time and location within the environment and second frame data (110) representing an image produced by the sensor at a second time and location within the environment. The method harmonizes (206) information about the first frame data, the second frame data and an overlapping subset of the point cloud data in order to determine a location within the point cloud data where at least one of the first frame and the second frame was produced, thereby localizing (208) the transportable apparatus within the environment.

Abstract: The present invention provides antibodies, for use in the treatment, suppression prevention of Filovirus disease, particularly Ebola virus disease. Also provided immunogens for use in eliciting such antibodies.

Abstract: Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.

Abstract: A method and system for determining extrinsic calibration parameters for at least one pair of sensing devices mounted on transportable apparatus obtains (202) image data (110) representing images captured by an image generating sensing device (102) of the pair at a series of poses during motion through an environment (120) by transportable apparatus (100). The method obtains (202) data (112) representing a 3D point cloud based on data produced by a 2D LIDAR sensing device (104) of the pair. The method selects (204) an image captured by the image at a particular pose. The method generates (210) a laser reflectance image based on a portion of the point cloud corresponding to the pose. The method computes (212) a metric measuring alignment between the selected image and the corresponding laser reflectance image and uses (214) the metric to determine extrinsic calibration parameters for at least one of the sensing devices.

Abstract: Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.

Abstract: Disclosed herein are methods of inducing neuronal outgrowth of a neuron. The methods comprise contacting the neuron with an agent that binds receptor protein tyrosine phosphatase ? (RPTP?), to thereby induce neuronal outgrowth of the neuron. The agent may induces clustering of RPTP? and/or inhibit binding of chondroitin sulfate proteoglycan (CSPG) to RPTP?. Examples of suitable agents are heparan sulfate proteoglycan, heparan sulfate, heparan sulfate oligosaccharides, or heparin oligosaccharides. Additional agents are also disclosed. The neuron can be a CNS neuron or peripheral neuron. Also disclosed herein are methods of treating neuronal injury in a subject comprising, administering to the subject an agent that binds RPTP?. Administration may be to a site of neuronal injury, to thereby induce neuronal outgrowth at the site of neuronal injury.

Abstract: Navigation data is generated by receiving (502) a new experience data set (321) relating to a new experience capture. At least one stored experience data set (320) relating to at least one previous experience capture is also received (504). An experience data set includes a set of nodes, with each node comprising a series of visual image frames taken over a series of time frames. A candidate set of said nodes is obtained (506) from the stored experience data set that potentially matches a said node in the new experience data set, and then a check (508) if performed to see if a node in the candidate set matches the node in the new experience data set. If the result of the checking is positive then data relating to the matched nodes is added (510) to a place data set useable for navigation, the place data set indicating that said nodes in different said experience data sets relate to a same place.

Abstract: The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype.

Abstract: A supramolecular metal-organic framework material is a reaction product of a copper compound, a trialkylamine represented by Chemical Formula 1, and benzene substituted with 3 or more carboxyl groups.

Abstract: A method of determining extrinsic calibration parameters for at least one sensor (102, 104, 106) mounted on transportable apparatus (100). The method includes receiving (202) data representing pose history of the transportable apparatus and receiving (202) sensor data from at least one sensor mounted on transportable apparatus. The method generates (204) at least one point cloud data using the sensor data received from the at least one sensor, each point in a said point cloud having a point covariance derived from the pose history data. The method then maximizes (206) a value of a quality function for the at least one point cloud, and uses (208) the maximized quality function to determine extrinsic calibration parameters for the at least one sensor.

Abstract: The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Serum from patients with varying degrees of hepatic scarring induced by infection with the hepatitis C virus (HCV) was analysed. Several proteins associated with liver scarring and/or viral infection were identified. These proteins include the inter-?-trypsin inhibitor heavy chain H4 fragments, complement factor H-related protein 1, CD5L, Apo L1, and ?2GPI. Increased and decreased thiolester cleavage of a2M and Complement C3, respectively, was also detected. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed.